NEW YORK, May 17, 2022 (GLOBE NEWSWIRE)  — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, reminds its shareholders to vote in favor of the proposed business combination with BioTE Holdings, LLC (“Biote”) and the

Company accelerates expansion and reiterates 2022 guidance Net sales of $37 million in the quarter, an 18% increase year-over-year from the first quarter of 2021. First quarter procedural revenue grew at 21.2% year-over-year. Adjusted EBITDA of $12 million, a 20% increase year-over-year.1 The

Record net sales of $139.4 million for the full year, a 20% increase year-over-year. Record net sales of $37.5 million in the fourth quarter, a 22% increase period-over-period. EBITDA of $36 million, a 9% increase year-over-year. 1 In December 2021, Biote entered into a business combination

Biote is a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization space. Biote-certified practitioners provide personalized therapies to their patients who experience hormone imbalances. Biote is an established company with projected revenue of

IRVING, Texas –BioTE Holdings, LLC (“Biote”), a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization space, today announced that its management team will be participating virtually in the ICR Conference 2022.  Terry Weber, Biote’s Chief

RANKING PRESENTED BY THE WOMEN PRESIDENTS’ ORGANIZATION & JPMORGAN CHASE COMMERCIAL BANKING Irving, Texas – October 15, 2021 – Biote has been announced as one of the 50 Fastest-Growing Women-Owned/Led Companies in the 14 th  annual ranking compiled by The  Women Presidents’ Organization  (WPO) in

BIOTE ANNOUNCED THE APPOINTMENTS OF DR. MARK CONE AND DANA JACOBY TO THE COMPANY’S BOARD OF DIRECTORS. CONE AND JACOBY BRING SIX DECADES OF COMBINED EXPERIENCE IN HEALTHCARE PRACTICE AND BUSINESS LEADERSHIP TO THE COMPANY’S BOARD. IRVING, Texas–( BUSINESS WIRE )– Biote Medical , a hormone

BIOTE REPORTS COMPLICATION RATES UNDER 1% IN STUDY EVALUATING THERAPY COMPLICATIONS AND CONTINUATION IRVING, Texas–( BUSINESS WIRE )–Delivering testosterone via bioabsorbable pellets inserted under the skin is a low-risk approach to long-term hormone therapy for women and men, according to

Real World Data of 2,337 Patients Over Nine Years Is Second Long-Term Study Showing Such Benefits IRVING, Texas--( BUSINESS WIRE )--Women who took testosterone via hormone pellets as part of bioidentical hormone replacement therapy (BHRT) had a 35.5% lower incidence of invasive breast cancer